Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment - Full Text View

Sponsored by:	University of Konstanz
Information provided by:	University of Konstanz
ClinicalTrials.gov Identifier:	NCT00783185

Purpose

Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.

Point of interest is psychopathology and consumerism.

Condition	Intervention	Phase
Psychotic Disorders Marijuana Abuse Intervention	Behavioral: Cannabis-Consumption-Reduction-Training Behavioral: Social competence Training	Phase I

MedlinePlus related topics: Dual Diagnosis Marijuana Psychotic Disorders

Drug Information available for: Cannabis GW-1000

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment
Official Title:	Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-Term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis

Further study details as provided by University of Konstanz:

Primary Outcome Measures:

PANSS Positive and Negative Symptom Scale [ Time Frame: post intervention, six months follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Urinstatus for cannabinoids [ Time Frame: weekly during and post intervention, follow-up ] [ Designated as safety issue: No ]

Estimated Enrollment:	50
Study Start Date:	January 2006
Estimated Study Completion Date:	January 2010
Estimated Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
ACT: Experimental Anti-Cannabis-Consumption-Training	Behavioral: Cannabis-Consumption-Reduction-Training 8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
CG: Active Comparator Control group	Behavioral: Social competence Training 8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences

Detailed Description:

Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.

Cannabis misuse is a known risk factor for recurrence of psychosis.

A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.

The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).

Admission to groups is randomly.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical diagnosis of schizophrenia and disorders with psychotic features
Misuse of cannabis during 12 months preceding admission to hospital

Exclusion Criteria:

Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation)
Discharge from hospital before completion of training

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00783185

Contacts

Contact: Hans Watzl, Dr.	00497531977 ext 245	Hans.Watzl@uni-konstanz.de
Contact: Caroline I von Thomsen-Rothfuß, Dipl.Psych.	0049753188 ext 4618	Caroline.von-Thomsen@uni-konstanz.de

Locations

Germany, Baden-Württemberg
University of Konstanz	Recruiting
Konstanz, Baden-Württemberg, Germany, 78462
Contact: Hans Watzl, Dr 00497531977 ext 245 Hans.Watzl@uni-konstanz.de
Contact: Caroline I von Thomsen-Rothfuß, Dipl.Psych 0049753188 ext 4618 Caroline.von-Thomsen@uni-konstanz.de
Principal Investigator: Hans Watzl, Dr.

Sponsors and Collaborators

University of Konstanz

Investigators

Principal Investigator:

Hans Watzl, Dr.

University of Konstanz

More Information

Responsible Party:	University of Konstanz ( Hans Watzl, Dr. )
Study ID Numbers:	CRET
Study First Received:	October 30, 2008
Last Updated:	October 30, 2008
ClinicalTrials.gov Identifier:	NCT00783185
Health Authority:	Germany: Court of psychotherapists in Baden-Württemberg, Stuttgart, Germany

Keywords provided by University of Konstanz:

psychotic disorders
cannabis
intervention

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

Psychotic Disorders
Marijuana Abuse
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 16, 2009